The relationship between the efficacy of targeted therapy and gene mutation in medullary thyroid carcinoma and radioiodine-refractory differentiated thyroid carcinoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200061324

Enrollment

Unknown

Registered

2022-06-21

Start date

2022-07-01

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

medullary thyroid carcinoma and radioiodine-refractory differentiated thyroid carcinoma

Interventions

none:none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Metastases showed no iodine uptake on whole-body scans after the first radioiodine treatment; 2. Functional metastases that originally ingested iodine gradually lost their ability to absorb iodine; 3. Some metastases take iodine, some metastases do not take iodine, and can be displayed by other imaging methods such as 18F-FDG PET/CT, CT or MRI; 4. Although the iodine-uptake metastases maintained their iodine-uptake ability after repeated radioiodine treatment, the disease progressed within 1 year, including the gradual growth of the lesions.

Exclusion criteria

Exclusion criteria: 1. Patients with non-medullary thyroid cancer and iodine-refractory differentiated thyroid cancer; 2. Patients who cannot be effectively followed up.

Design outcomes

Primary

Measure	Time frame
Overall survival;Progression-free survival;	—

Countries

China

Contacts

Public ContactBin Zhang

zbnuclmd@126.com+86 13915519962

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026